"Acrylamides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Colorless, odorless crystals that are used extensively in research laboratories for the preparation of polyacrylamide gels for electrophoresis and in organic synthesis, and polymerization. Some of its polymers are used in sewage and wastewater treatment, permanent press fabrics, and as soil conditioning agents.
Descriptor ID |
D000178
|
MeSH Number(s) |
D02.065.122 D02.241.081.069.094
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Acrylamides".
Below are MeSH descriptors whose meaning is more specific than "Acrylamides".
This graph shows the total number of publications written about "Acrylamides" by people in this website by year, and whether "Acrylamides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 0 | 1 | 1 |
2005 | 2 | 0 | 2 |
2006 | 1 | 0 | 1 |
2014 | 0 | 1 | 1 |
2015 | 1 | 0 | 1 |
2016 | 2 | 2 | 4 |
2017 | 0 | 1 | 1 |
2018 | 2 | 1 | 3 |
2019 | 0 | 2 | 2 |
2020 | 1 | 4 | 5 |
2021 | 0 | 1 | 1 |
2022 | 0 | 1 | 1 |
2023 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Acrylamides" by people in Profiles.
-
Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC. J Thorac Oncol. 2024 Mar; 19(3):500-506.
-
A small molecule exerts selective antiviral activity by targeting the human cytomegalovirus nuclear egress complex. PLoS Pathog. 2023 Nov; 19(11):e1011781.
-
Osimertinib, Surgery, and Radiation Therapy in Treating Patients with Stage IIIB or IV Non-Small Cell Lung Cancer with EGFR Mutations (NORTHSTAR). Ann Surg Oncol. 2022 08; 29(8):4688-4689.
-
p21-activated kinases as viable therapeutic targets for the treatment of high-risk Ewing sarcoma. Oncogene. 2021 02; 40(6):1176-1190.
-
Targeting PAK4 Inhibits Ras-Mediated Signaling and Multiple Oncogenic Pathways in High-Risk Rhabdomyosarcoma. Cancer Res. 2021 01 01; 81(1):199-212.
-
Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib. Cancer Res. 2020 11 01; 80(21):4840-4853.
-
Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer. Lung Cancer. 2020 11; 149:33-40.
-
Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann Oncol. 2020 11; 31(11):1536-1544.
-
Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry. Nat Commun. 2020 08 26; 11(1):4268.
-
Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer. Cancer. 2020 01 15; 126(2):373-380.